Biopharma Breaking News Reporter (UK-based)

TITLE: Biopharma Breaking News Reporter (UK-based) 

SALARY: £45,000 to £55,000


EXPERIENCE: One to two years


Endpoints News is seeking a UK-based junior biotech and pharma reporter to join our breaking news team, who will work closely with our global editors to help write stories for our morning newsletter.

In this role, you’ll write two to three stories a day and will cover daily news on the biotech and pharma industries. You’ll coordinate closely with our US-based team and our other editors, getting ahead of the American morning to get our coverage out on time.

Stories range from a few hundred words on fast-moving news items like clinical trial results, M&A deals and CEO changes, to longer reporting-driven pieces on business and scientific developments. You’ll react to news and write a lot of copy, and we’re busy enough that there will be ample opportunities for ambitious candidates to hunt scoops and get involved in bigger projects as they learn the beat and grow as a journalist.

You’re the right candidate if you have one to two years of experience covering biotech, pharma or medical science for a trade or specialty publication. You should know what a p-value is and the difference between a biologic and a small molecule, and be ready to expand your skills as a reporter and writer with coaching and support from the team.

This role is part of a group of journalists who report to our deputy editor for newsletters.


Endpoints News, a leading B2B media company, was founded in 2016 with a clear mission: deliver the best news product in biopharma and become an essential read for industry leaders across the globe. Seven years later, we now have 164,000 subscribers and a team of journalists and staff in the US, Europe, and Asia. We’re read daily by thousands of innovative biotechs and every top 50 pharmaceutical company in the world. Our editorial ambitions continue to grow as we complement our breaking news and daily analysis with original scoops, in-depth features and live journalism at the industry’s most important gatherings.

We are now a part of the Financial Times family